Regulatory Affairs IV Team, Division of Corporate Development 107, Ihyeon-ro30beon-gil, Giheung-gu Yongin-si, Gyeonggi-do, Korea

May 12, 2021

## Letter of Declaration

Dear Sir/Madam who might concern,

We, Green Cross Corporation, the manufacturer of GC FLU Quadrivalent Pre-filled syringe inj. hereby declare that the following strains are recommended composition of influenza virus vaccines for use in the 2021-2022 Northern hemisphere influenza season and are used for the production of GC FLU Quadrivalent PFS inj. 2021-2022:

H1N1: A/Victoria/2570/2019 IVR-215

N3N2: A/Cambodia/e0826360/2020 IVR-224

B-Vic: B/Washington/02/2019B-Yam: B/Phuket/3073/2013

The applied CoPP can be issued on 30<sup>th</sup> June 2021 from the Ministry of Food and Drug Safety(MFDS) after approval change in Republic of Korea.

## Attachment

Recommended composition of influenza virus vaccines for use in the 2021-2022
Northern hemisphere influenza season

Sincerely,

Younchul Shin

Younchul Shin Head of Regulatory Affairs IV Team Green Cross Corporation

The document contains confidential and proprietary information. It should not be copied or disclosed to any third party without the written permission of Green Cross Corp. The document shall be used for registration/regulatory purpose only and must be reviewed and approved with correspondent date and signature prior to release.